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Effect of L.carnitine on sodium transport In erythrocytes from dialyzed
uremic patients. Red blood cell (RBC) sodium transport systems were
studied by cation flux methodology, measuring both the ouabain—sensi-
tive Na-K pump and the ouabain—insensitive Na-K cotransport (CoT),
as well as the Na-lithium (Li) countertransport (Cr1'), in eight patients
on chronic hemodialysis and a control group of eight normal individu-
als. Intracellular sodium content and passive Na permeability were also
determined. The effect of L-carnitine on RBC sodium transport in the
uremic group was evaluated by supplementation with oral (1 g/day) and
i.v. (1 g post-hemodialysis) L-carnitine for 60 days. Mean Na efiuux
through the ouabain—sensitive Na-K pump was 30.7% lower in uremic
patients than in controls (3.49 1.52 vs. 5.04 0.72 mmol/liter
RBCxhr; P < 0.025). Intracellular Na content was higher in uremic
patients (11.57 3.38 vs. 8,86 0.88 mEq/liter RBC; P < 0.05), but no
differences were found in Na-K CoT, Na-Li Cr1' or passive Na
permeability. L-carnitine treatment increased the ouabain—sensitive Na
efflux in uremic patients (4.76 1.6vs. 3.49 1.52mmol/liter RBC Xhr;
P < 0.05), with no change in CoT, CTT, intracellular Na content or
passive Na permeability. We conclude that L-carnitine deficiency may
play a major role in uremic Na-K pump disfunction.
Cationic transport systems in the red blood cell (RBC), the
most commonly employed cell model, have been clearly defined
and differentiated by several authors, as follows: Na-K adeno-
sintriphosphatase (Na-K ATPase) inhibited by ouabain, Na-K
cotransport (CoT) inhibited by furosemide, and Na-Na or Na-Li
countertransport (CTT) inhibited by phloretin [1—4].
During the last few years attempts have been made to
elucidate the effect of uremia on these transport systems.
Although the Na-K pump mechanism has been thoroughly
studied, it is only recently that Na-K CoT and Na-Li CTT
functions in end—stage renal disease (ESRD) have been inves-
tigated [5, 61.
The most frequent finding is that erythrocytes from uremic
patients present deficient Na-K ATPase activity due to causes
as yet unclear. In this regard, the existence of a circulating
Na-K pump inhibitor was suggested by the depression observed
in pump activity after incubation of normal RBCs with uremic
plasma [7, 8]. As regards the chemical nature of this inhibi-
tor(s), it is noteworthy that Tamura et al have recently reported
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that circulating free fatty acids (FFA) are endogenous inhibitors
of the Na-K ATPase [91. The importance of L-carnitine in fatty
acid metabolism has hinted that its deficiency may play a major
role in uremic Na-K pump disfunction.
Accordingly, this study evaluates the various sodium trans-
port systems (Na-K pump, CoT, and CTT), together with
intracellular Na content and passive Na permeability immedi-
ately prior to dialysis, in a group of uremic patients on chronic
hemodialysis, and compares findings with a sex— and age—
matched control group. The response of erythrocyte transport
systems in uremic patients to 60 days oral and intravenous
supplementation with L-carnitine was subsequently evaluated.
Methods
Patients
Eight patients, five male and three female, with ESRD of
varying etiologies were studied. Their ages ranged from 28 to 64
years, with a mean of 50.5 13.8, and they had been on four
hour, thrice—weekly intermittent heniodialysis for 25 to 101
months, with a mean of 50.25 23.03 months. All patients were
norrflotensive with predialysis mean systolic and diastolic BP of
125 14 and 81 9 mm Hg, respectively. All were stable and
ambulatory, with no intercurrent diseases. None were on digital
or diuretics or had received transfusions within the last six
months. The control group consisted of eight normotensive
individuals, with mean systolic and diastolic BP of 126 10 and
78 6 mm Hg, respectively, with no significant medical
problems, five male and three female, whose ages ranged from
31 to 65 years (50.7 13.3 years).
Study design
At day zero (0) of the study, 20 ml of blood were taken with
a heparinized syringe to determine ouabain—sensitive Na efflux
(Na-K pump), Na-K CoT, Na-Li CTT, intracellular Na content
and passive Na permeability. Blood samples were obtained
before dialysis, in the morning and after fasting. At immediate
post-dialysis on day 0, uremic patients were put on L-carnitine
(ALBICAR, Casasco, ingestible 1 g vials) at the rate of 1
g/day by oral route plus 1 g i.v. every post-dialysis (1 g i.v.
vials). L-carnitine supplementation was given for 60 days.
During the two weeks prior to day 0, baseline determinations
of various humoral parameters were carried out, and then
repeated at day 62.
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N Pre Post
Na-K pump
mmol/literRBC x hr 5.04 0.72 3.49 1.52° 4.76 1.6"
Na-K C0T
mmol/liter RBC x hr 0.3 0.08 0.31 0.23 0.33 0.2
Na-Li CTT
inmolIliterRBC x hr 0.33 0.05 0.33 0.11 0.36 0.19
Na content
mEqIlllerRBC 8.86 0.88 11.57 3.38° 11.25 2.12
Na permeability
per hr 0.026 0.012 0.025 0.011 0.026 0.013
Blood samples from the control group were also taken in the
morning after fasting to determine ouabain—sensitive Na-efflux,
CoT, CTT, intracellular Na content and passive Na permeability.
Methods
Blood sampling was performed before hemodialysis in two
heparinized tubes: one was for CTT, while the other was for
CoT and Na-K pump evaluation.
After spinning for 10 minutes at 6000 g at 4°C in a cooled
centrifuge, the RBC pellet was washed four times with the
following solutions: for CTT, (mM) MgCI2 75, sucrose 85, and
Tris-MOPS 10 pH 7.4 at 4°C; for CoT, (mM) choline chloride
149, MgCI2 1 and Tris-MOPS 10 pH 7.4 at 4°C.
Na-Li CTT measurement, This was done according to the
methods described by Canessa et al [101 and Adragna et al [11].
1. For Li loading, 2 ml of washed RBC (hematocrit 20%)
were incubated for three hours at 37°C in a loading solution
(mM: LiCI 150, Tris-MOPS 10, pH 7.4 at 37°C, glucose 10). Li
was removed by washing six times with a solution of (mM)
MgCl2 75, sucrose 85, and Iris-MOPS 10, pH 7.4 at 4°C. A 50%
cell suspension in washing solution was used for measurements
of hematocrit, hemoglobin, intracellular Na content and fluxes.
2. For flux measurement, Li effiux was measured in Mg and
Na medium (4% to 5% hematocrit). Na medium contained
(mM): Na 150, glucose 10, Tris-MOPS 10, pH 7.4 at 37°C, and
ouabain 0.1. Mg medium contained (mM): MgCl2 75, Tris-
MOPS 10, pH 7.4 at 37°C, glucose 10, sucrose 85, and ouabain
0.1. The 50% suspension was diluted to a 4 to 5% hematocrit
with the cooled (4°C) Mg and Na media, and the resultant cell
suspension divided into three portions and incubated for 60
minutes at 37°C. Li concentration was determined in the Mg
and Na media using an atomic absorption spectrophotometer.
Na-K pump and CoT maximum Na efflux rate measurement.
Measurements were carried out with Na loaded RBC by the
nystatin method as described by Canessa et al [10].
I. For Na loading, 2 ml of washed RBC were added to 10 ml
of loading solution (mM: NaCI 70, KCI 70, sucrose 55, Iris-
MOPS 10, pH 7.4 at 4°C) containing 150 A of nystatin solution
(10 mg in 2.5 ml dimethylsulfoxide), and incubated for 20
minutes at 4°C. Nystatin was removed by centrifuging at room
temperature and washing four times at 35°C with (mM) NaC1 70,
KCI 70, Iris-MOPS 10, pH 7.4 at 4°C, sucrose 55, K2HPO4
buffer 1, pH 7.4, glucose 10, and albumin 0.1%. In the first wash
Fig. 1. Values for ouabain—sensitive sodium efflux (Na-K pump) in so-
dium loaded RBC from normal controls (N) (N 8); and in dialysis
patients (N = 8) before (Pre) and after (Post) L-carnitine administration.
the cells were equilibrated for 10 mintues in the water bath, and for
four minutes in the last three washes. The cells were subsequently
washed with cold (4°C) choline washing solution (mM: choline
chloride 149, MgCl2 1, Iris-MOPS 10, pH 7.4 at 4°C). A suspen-
sion at 50% hematocrit was made for measurements of hemoglo-
bin, hematocrit, intracellular Na content and fluxes.
2. For flux measUrement to measure Na-K pump function,
0.2 ml of the 50% suspension Were added to 7 ml of medium
(mM: choline chloride 140, KC1 10, MgCI2 1, Tris-MOPS 10, pH
7.4 at 37°C, glucose 10) without and with ouabain (0.1 mM). To
measure CoT, 0.8 ml of the 50% suspension were added to 7 ml
of medium (mM: choline chloride 148, MgCI2 1, Tris-MOPS 10,
pH 7.4 at 37°C, glucose 10, ouabain 0.1) without and with
furosemide, 1 mit (33 mg in 100 d of Iris base I M—furosemide
1 M—, and then made up to 1 m't with medium). After the
addition of the cell suspension to each flask, 1.5 ml of the flux
medium was put into each of five tubes. Duplicate tubes were
incubated at 37°C for five minutes, and triplicate tubes for 25
minutes for pump medium and 65 minutes for CoT medium.
Cellular Na content was measured by means of suitable stan-
dards. All solutions employed for flux measurement required
adjustment to 298 5 mOsm/liter. Two normal controls for
Na-K pump and CoT were repeated five times, obtaining a
variation coefficient lower than 10%. Hemoglobin concentra-
tion was measured throughout the experiment, discarding flux
measurements when variations were greater than 3% versus the
original cells.
In vitro incubation with L-carnitine. In four uremic patients
L-carnitine effect on RBC Na-K pump was tested in vitro. In
this study, 0.5 mg of free L-carnitine were added to 10 ml of
blood (to get 300 tmol/liter, blood concentration usually ob-
tained with the carnitine dosage used in this study [12]), and
incubated for 60 minutes. Ouabain—sensitive Na efflux post-
incubation was then compared with basal values in the same
patients.
Other measurements
Baseline determinations of hematocrit, urea, uric acid, cre-
atinine, natremia, kalemia, calcemia, and phosphatemia, as well
Table 1. Sodium transport systems, sodium content and passive
sodium permeability in RBC from normal controls (N) (N = 8); and in
dialysis patients (N = 8) before (Pre) and after (Post) L-Carnitine
administration
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Fig. 3. Values for sodium—stimulated lithium efflux (countertransport)
in RBC from normal controls (N) (N = 8); and in dialysis patients (N =
8) before (Pre) and after (Post) L-carnitine administration.
Na-K CoT
No significant differences were found in ouabain—insensitive,
furosemide—sensitive Na efflux for uremic patients versus con-
trols (0.31 0.23 vs. 0.3 0.08 mmol/liter RBCxhr; NS).
L-carnitine treatment failed to modify Na-K CoT in uremic
patients (0.31 0.23 vs. 0.33 0.2 mmol/liter RBCxhr; NS)
(Fig. 2).
Na-Li CTT
There was no significant difference between Na-stimulated
lithium efilux in uremic patients and controls (0.33 0.11 vs.
0.33 0.05 mmollliter RBCxhr; NS) and L-carnitine adminis-
tration had no effect on the former group (0.33 0.11 vs. 0.36
0.19 mmoLfliter RBCxhr; NS) (Fig. 3).
Intracellular Na content
Post
NS NS
Fig. 2. Values for ouabain—insensitive, furosemide—sensitive sodium
efflux (cotransport) in sodium—loaded RBC from normal controls (N) (N
= 8); and in dialysis patients (N = 8) before (Pre) and after (Post)
L-carnitine administration.
as triglycerides, total cholesterol, HDL-cholesterol, and total
lipids, were carried out and repeated at day 62 of the study.
Blood samples were obtained before dialysis, in the morning,
and after fasting.
Hemodialysis
All patients underwent four—hour hemodialysis sessions em-
ploying the same cuprophane ifiters (Travenol 23.08) having 8 u
membrane thickness and 1.4 m2 surface. Continuous heparin-
ization was employed, with an initial mean dose of 2250 250
IU and 1750 250 IU hourly. Hemodialysis was carried out
employing the usual technique, adjusting ultrafiltration to the
patient's clinical needs. Bath preparation was automatic through-
out, keeping Na concentration at 137 to 139 mEq/liter.
Statistical analysis
Student's t-test was employed to evaluate statistical signifi-
cance. The various correlations were evaluated by linear re-
gression (Pearson's r). All results are expressed as mean SD.
Mean intracellular Na content in uremic patients was 30.5%
higher than the control group mean (11.57 3.38 vs. 8.86
0.88 mEq/liter RBC; P C 0.05), but L-carnitine administration
failed to modify values in the uremic group (11.57 3.38 vs.
Results 11.25 2.12 mEq/liter RBC; NS) (Fig. 4).
Na-K pump, Na-K CoT, Na-Li CTT, intracellular Na con-
tent, and passive Na permeability results are outlined in Passive Na permeability
Table 1. Na permeability was measured as the effiux rate constant for
Na from Na-loaded cells in the presence of ouabain and
Na-K pump furosemide. The effiux rate in mmol/liter RBC x hr was factored
Mean value for ouabain-sensitive Na efliux in uremic patients
was 30.7% lower than mean value in controls (3.49 1.52 vs.
5.04 0.72 mmol/liter RBCXhr; P C 0.025). If the uremic
patient with the lowest value is excluded (Fig. 1), mean Na
efflux becomes 3.85 1.24 mmol/liter RBC x hr, which is still
significantly lower than normal mean value (P <0.05).
by the initial intracellular Na concentration and expressed as a
rate constant. Passive Na permeability was not different be-
tween uremic patients and normal subjects (0.025 0,011 vs.
0.026 0.012 per hr; NS), and L-carnitine treatment did not
modify passive Na permeability in uremic patients (0.025
0.011 vs4 0.026 0.013 per hr; NS).
L-carnitine administration to the uremic patients led to a
36.2% Na efflux increase as regards baseline values (3.49 1.52 In vitro incubation with L-carnitine
vs. 4.76 1.6 mmollliter RBC x hr; P C 0.05). Post-L-carnitine No significant differences were found in ouabain—sensitive
mean value was only 5.5% below the control group mean (4.76 Na efilux in uremic RBCs after in vitro incubation with L-
1.6 vs. 5.04 0.72 mmol/liter RBCXhr; NS) (Fig. 1). carnitine, when compared with basal values in the same pa-
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tients (3.37 0,91 vs. 3.46 0.85 mmol/liter RBCxhr; NS)
(N = 4).
General measurements
Following L-carnitine administration there was a very signif-
icant increase in all eight uremic hematocrit values (24.9 2.7
vs. 22.25 3.6%; P < 0.001) (Fig. 5), but no changes were
observed in the remaining parameters (Table 2).
Statistical correlations
Using linear regression no significant correlations were found
for: ouabain—sensitive Na efflux versus intracellular Na (in both
uremic and normal subjects); Na-K pump versus hematocrit;
Na-K CoT versus kalemia; intracellular Na versus CoT or CTT;
or Na pump, CoT and CTT versus total cholesterol, HDL-
cholesterol, triglycerides or total lipids.
Discussion
A deficient Na-K ATPase function in patients with chronic
renal failure was first reported by Welt, Sachs and Manus over
20 years ago [13]. These authors detected in 25% of the uremic
patients examined an increase in intracellular Na content,
together with a decrease in RBC Na-K pump activity [13]. In
1973, Cole demonstrated a decrease in erythrocyte Na-K ATPase
activity in most uremic patients tested [14]. Later, several
authors reported similar findings [7, 15, 16], although recently
Corry et al failed to detect this defect in erythrocyte Na-K
ATPase activity in a group of 36 patients on chronic dialysis
(hemodialysis and chronic ambulatory peritoneal dialysis) [5].
Likewise, it is worthwhile pointing out that alterations have
been detected in Na-K pump activity in leucocytes [17], brain
[18], intestine [19] and muscle cells [20] from uremic subjects.
The cause of this deficient Na-K pump activity in chronic
renal failure is far from clear. A deficiency in the pump's energy
substrate, the ATP itself, may perhaps be ruled out, since the
pump is saturated with ATP under physiological conditions
[21], and moreover, ATP concentration is usually increased in
uremic erythrocytes [22].
The existence of a circulating Na-K ATPase inhibitor was
suggested by the depression observed in pump activity after
incubation of normal RBCs with uremic plasma [7, 8]. As
regards this "endogenous—ouabain" model, Bohan, Potter and
Bourgoignie have detected a low molecular weight substance in
urine from uremic dogs, which displaced ouabain from cellular
receptors in renal cortical membranes [23], and Graves, Brown
and Valdes have reported the existence of a digoxin—like
substance in serum from uremic patients [24]. Although the
chemical nature of these Na-K ATPase inhibitors has not been
exactly defined [25, 26], it is noteworthy that several authors
have shown that unsaturated fatty acids inhibit Na-K ATPase
and also displace ouabain from the enzyme [27, 28]. In this
regard, Tamura et al have recently demonstrated that plasma
linoleic and oleic acids are endogenous Na-K pump inhibitors
[9]. Moreover, plasma levels of these fatty acids markedly
increased during acute volume expansion [9].
With respect to L-carnitine (L-3-hydroxy-4-N-trimethylami-
nobutyric acid), it is well known that this substance is the
20 -
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Table 2. Laboratory parameters in dialysis patients (N = 8) before
(Pre) and after (Post) L-carnitine administration
a
Pre Post
Hct %
Serum urea mg/dl
Serum creatinine mgldl
Serum Na mEqiliter
Serum K mEqiliter
Serum Ca mg/dl
Serum P mgldl
Serum uric acid mg/dl
Total serum cholesterol mgldl
Serum HDL-cholesterol mg/dl
Serum triglycerides mgldl
Total serum lipids mgldl
22.25 3.6
155 28
11.9 3
141 0.2
5.3 0.5
8.6 0.6
5.6 1.6
8.4 0.9
176 48
27.2 20
175 130
772 284
24.9 2.7a
145 43
11.1 2.8
142 2.1
5.5 0.2
8.8 0.6
5.3 1.8
7.5 1.5
189 36
30 19
191 107
787 135
a p < 0.001
N Pre Post
P<0.05 NS
Fig. 4. Values for intracellular sodium concentration in RBC from
normal controls (N) (N = 8); and in dialysis patients (N = 8) before
(Pre) and after (Post) L-carnitine administration.
30
28
26
a)
>
22-
C-)0
E
a)I
18
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P<0.001
Fig. 5. Hematocrit values from dialysis patients (N = 8) before (Pre)
and after (Post) L-carnitine administration.
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natural carrier of fatty acids from the cellular cytoplasm to the
mitochondrial matrix, where they undergo p-oxidation [29].
Patients on chronic hemodialysis present severe serum and
tissue L-camitine deficiency due to a combination of inadequate
intake, impaired synthesis and excessive loss during dialysis
(L-carnitine molecular wt: 161 dalton) [30, 31].
By decreasing FFA oxidation, carnitine deficiency appears to
play an important role in the multifactorial pathogenesis of
hyperlipidemia in uremic patients [32]. In fact, several authors
have reported an improvement in plasma lipid profile following
L-carnitine administration in dialyzed uremic patients [12, 33,
34]. Besides, it has been observed that during hemodialysis the
drop in serum L-carnitine levels is accompanied by a rise in
serum FFA [35]. This peak in FFA levels is markedly reduced
after L-carnitine supplementation for 1 week [36].
Under normal conditions the kidney metabolizes circulating
fatty acids, and FFA oxidation provides 10 to 20% of the renal
energy requirements [37, 38]. The decrease in renal FFA
metabolism may contribute to the increased levels of these
Na-K pump inhibitors in uremia.
Since in vitro incubation with L-carnitine did not modify
Na-K ATPase activity, we may rule out any direct effect of the
drug on RBC Na-K pump. Therefore, we conclude that L-
carnitine administration might increase fatty acid transport and
oxidation in uremic patients, thus decreasing the plasma con-
centration of these Na-K ATPase inhibitors. The removal of
these "ouabain-.like" factors might explain the enhanced Na-K
pump activity observed in the present study following L-
carnitine supplementation in dialyzed uremic patients.
In the present study a significant increase in hematocrit value
after L-cnrnitine administration was detected in all cases, in
agreement with previous literature [12]. Vacha et al suggested
that L-carnitine might improve the lipid metabolism in erythro-
cyte membrane, thus explaining the hematocrit increase [12].
This hypothetical variation in RBC membrane composition
after L-carnitine treatment could also lead to an increase in the
number of Na-K pump units per RBC. In addition to the FFA
model, this alternative hypothesis could explain the partial
recovery of RBC Na-K pump activity after L-carnitine admin-
istration in uremic patients. In this regard, it is noteworthy that
Cheng, Kahn and Kaji have recently proposed that a decreased
synthesis of Na-K pump sites in erythroid precursors might
account for the uremic Na-K ATPase defect [39].
In our study L-carnitine treatment increased Na-K ATPase
activity but failed to decrease intracellular Na content, thus
suggesting that the higher Na content in uremic RBCs is not
related to the Na-K pump defect. Regarding that CoT, CTT and
passive Na permeability were not affected by uremia or L-
carnitine treatment, a different Na transport system might be
responsible for the increased intracellular Na in uremia.
In addition to the ouabain—sensitive Na-K pump, the RBC
contains ouabain—resistant transport systems, such as the Na-K
CoT and the Na-Na or Na-Li CTT. The Na-K CoT transports
Na and K in the same direction through the RBC membrane,
either inwards or outwards, depending on ionic transmembrane
chemical gradients [3, 40, 41]. Recently, marked Na-K CoT
depression has been reported in dialyzed uremic patients,
which the authors partly attribute to the moderate hyperkalemia
observed in the group under study [5]. In our study, Na-K CoT
was not different between uremic patients and normal subjects,
in spite of the former's moderate hyperkalemia (5.3 0.5
mEq/liter). L-carnitine treatment did not modify uremic Na-K
CoT activity.
The Na-Li CTT removes intracellular lithium from lithium—
loaded erythrocytes, in a 1:1 exchange ratio with extracellular
Na [2]. In a recent report, Woods, Parker and Watson have
demonstrated that Na-Li Cfl maintains normal activity in
uremia by means of the stimulating action exerted by a sus-
pected dialyzable plasma factor [61. The removal of this factor
leads to a fall in RBC Na-Li CTT immediately after dialysis. In
our study Na-Li CTT was not different between uremic subjects
and controls, with no change in uremic Na-Li Cfl activity after
L-carnitine treatment.
Conclusions
A deficient Na-K ATPase activity was detected in our pa-
tients on chronic hemodialysis, in close agreement with most
published findings. Besides, intracellular Na content proved
significantly higher in uremic patients as compared to normal
controls.
L-carnitine administration significantly improved erythrocyte
Na-K ATPase activity, but failed to modify Na-K CoT, Na-Li
CTT, intracellular Na content or passive Na permeability. A
highly significant increase in hematocrit was also observed in all
the uremic patients following L-carnitine administration.
Although the number of patients under study was hardly
enough to draw any definitive conclusions, our work does
support L-carnitine deficiency as a causative factor in erythro-
cyte Na-K ATPase defect in uremia, as well as its contributory
role in the development of anemia in chronic renal failure.
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